Sun Pharma successfully secured ₹7,816 crore in its latest fundraising round, yet it fell short of its ambitious ₹10,000-crore target. The company opted for five- and seven-year bonds, pricing them at 8.05% and 8.20% respectively. A significant ₹2,100 crore was raised through anchor investments to bolster this effort, although rising market yields have made investors cautious about committing funds.
More in Economy
Gold heads for sharpest weekly decline in four months on Fed rate outlook
October 23, 2026
Positive Breakout: These 5 stocks cross above their 200 DMAs
October 23, 2026
Global Market Today: Asian stocks slide after US tech rout
October 23, 2026
IPO-bound companies defer launches to avoid Jio mega issue
October 23, 2026
Financials, FMCG lead FPI sell-off; IT stocks buck the trend in first half of October
October 23, 2026
Adani Green Energy shares fall 4% after Q2 results. What are Jefferies, JM Financial saying?
October 22, 2026
Latest News
2 reasons to buy Porsche Cayenne Turbo Electric and 2 reasons not to
October 23, 2026
Gold heads for sharpest weekly decline in four months on Fed rate outlook
October 23, 2026
Positive Breakout: These 5 stocks cross above their 200 DMAs
October 23, 2026
Jailer 2 Day 8 Box Office – ஜெயிலர் 2 8வது நாள் வசூல் இவ்வளவா?.. பாக்ஸ் ஆஃபிஸ் நிலைமை என்ன?
October 23, 2026
திருமணத்துக்கு ராஷ்மிகா மந்தனாவை கெஞ்ச விட்ட விஜய் தேவரகொண்டா.. இதெல்லாம் ரொம்ப ஓவர் பாஸ்
October 23, 2026
Mint Quick Edit | Signs of trouble ahead: Is it finally time for supply-side reforms?
October 23, 2026